MOLECULAR DOCKING STUDY OF Fe(III) COMPLEXES CONTAINING SALEN-TYPE SCHIFF BASES
DOI:
https://doi.org/10.62985/j.huit_ojs.vol26.no5.695Từ khóa:
Fe(III) complexes, unsymmetrical salen-type Schiff bases, cytotoxicity, HepG2, KB cell line, molecular docking.Tóm tắt
Our previous work reported the synthesis of Fe(III) complexes containing unsymetrical salen-type Shiff bases from the reaction of 2-hydroxynaphthaldehyde with substituted salicylaldehyde. The cytotoxic activities of these compounds were then evaluated against KB and HepG2 cancer cell lines. The results indicated that Fe(III) complexes exhibited significant anticancer potential, with low IC₅₀ values ranging for both KB and HepG2. To further investigate the binding mode between the ligands and a biological target, molecular docking analysis was performed in this study. Epidermal growth factor receptor (EGFR) tyrosine kinase was chosen as a receptor model because of its relevance to anticancer drug development. The molecular docking results revealed that the stabilization of the Fe(III) complex-receptor was mainly influenced by the nature and position of substituents on the salicylidene moiety. Specifically, among six studied compounds, two high-potency complexes achieved a robust network of 16 interactions, including key salt bridges and attractive charge bonds with Asp831, which were absent in less active derivatives. These findings provide valuable insights into the potential inhibitory mechanisms of the synthesized Fe(III) complexes and support their potential development as novel anticancer agents targeting EGFR.
Tài liệu tham khảo
[1] W. Yang, Y. Hu, Y.-S. Yang, F. Zhang, Y.-B. Zhang, X.-L. Wang, J.-F. Tang, W.-Q. Zhong, and H.-L. Zhu, “Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents,” Bioorganic & Medicinal Chemistry, vol. 21, no. 5, pp. 1050–1063, 2013, doi: https://doi.org/10.1016/j.bmc.2013.01.013
[2] X.-Q. Sun, L. Chen, Y.-Z.Li, W.-H. Li, G.-X. Liu, Y.-Q. Tu, and Y. Tang, “Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors,” Acta Pharmacologica Sinica, vol. 35, no. 2, pp. 301-310, 2014, https://doi.org/10.1038/aps.2013.148
[3] S. Agrawal, “Drug-metal complexes in research-A review,” International journal of science managemnet and engineering research IJSMER, vol. 1, no. 1, pp. 10-11, 2016.
[4] Z. Ghanbari, M. R. Housaindokht, M. Izadyar, M. R. Bozorgmehr, H. Eshtiagh-Hosseini, A. R. Bahrami, M. M. Matin, and M. J. Khoshkholgh, “Structure-Activity Relationship for Fe(III)-Salen-Like Complexes as Potent Anticancer Agents,” The Scientific World Journal, pp. 1-10, 2014, doi: https://doi.org/10.1155/2014/745649
[5] R. Herchel, Z. Sindelar, Z. Travnicek, R. Zboril, and J. Vanco, “Novel 1D chain Fe(III)-salen-like complexes involving anionic heterocyclic N-donor ligands. Synthesis, X-ray structure, magnetic, 57Fe Mössbauer, and biological activity studies,” Dalton Transactions, no. 44, pp. 9870-9880, 2009, doi: https://doi.org/10.1039/b912676g
[6] K. I. Ansari, J. D. Grant, G. A. Woldemanriam, S. Kasiri, and S. S. Mandal, “Iron(III)-salen complexes with less DNA cleavage activity exhibit more efficient apoptosis in MCF7 cells,” Organic & Biomolecular Chemistry, vol. 7, no. 5, pp. 926-932, 2009, doi: https://doi.org/10.1039/b816858j
[7] Q. T. Nguyen, P. N. Pham Thi, and N.V. Tuyen, “Synthesis, spectral characterization, and in vitro cytotoxicity of some Fe(III) complexes bearing unsymmetrical salen-type ligands derived from 2-hydroxynaphthaldehyde and substituted salicylaldehydes,” Journal of Chemistry, vol. 2021, no.1, 2021, doi: https://doi.org/10.1155/2021/8028064
[8] P. Wee and Z. Wang, “Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways,” Cancers, vol. 9, no. 5, 2017, doi: https://doi.org/10.3390/cancers9050052
[9] P. Maity, J. Chatterjee, K. T. Patil, S. Arora, M. K. Katiyar, M. Kumar, A. Samarbakhsh, G. Joshi, P. Bhutani, M. Chugh, N. S. Gavande, and R. Kumar, “Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities,” Journal of Medicinal Chemistry, vol. 66, no. 5, pp. 3135-3172, 2023, doi: https://doi.org/10.1021/acs.jmedchem.2c01242
[10] S. Almahmoud, X. Wang, J. L. Vennerstrom and H. A. Zhong, “Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target,” Molecules, vol. 24, no. 11, 2019, doi: https://doi.org/10.3390/molecules24112159
[11] P. Huang, X. Xu, L. Wang, B. Zhu, X. Wang, and J. Xia, “The role of EGF-EGFR signaling pathway in hepatocellular carcinoma inflammatory microenvironment,” Journal of Cellular and Molecular Medicine, vol. 18, no. 2, pp. 218-230, 2014, doi: http:/doi.org/10.1111/jcmm.12153
[12] H. Takano, K. Kohno, N. Shiraishi, S.-I. Sato, K.-I. Asoh, M. Yakushinji, M. Ono, and M. Kuwano, “Altered expression of epidermal growth factor receptor gene in a classical multidrug-resistant variant of a human cancer cell line, KB,” Japanese Journal of Cancer Research, vol. 80, no. 4, pp. 373-379, 1989, doi: http:/doi.org/10.1111/j.1349-7006.1989.tb02322.x
